SPRYD4

Across TCGA pan-cancer cohorts, SPRYD4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SPRYD4 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SPRYD4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPRYD4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and OV show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where SPRYD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.374	0.822	<.001	25	view →
PDAC	OS	Quartile	II,III,IV	0.629	0.910	.019	7	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.891	.015	6	view →
OV	DFS	Tertile	All	0.923	0.612	.026	4	view →
UCEC	DFS	Median	II,III,IV	0.550	0.865	.027	4	view →
HNSC	OS	Median	All	0.801	0.893	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SPRYD4–CCRCC (DFS)

Open the CCRCC breakdown →